Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 CERTIFICATION OF THE CFO SECTION 906 - CELGENE CORP /DE/ | ex322certificationofthecfo.htm |
| EX-32.1 - EXHIBIT 32.1 CERTIFICATION OF THE CEO SECTION 906 - CELGENE CORP /DE/ | ex321certificationoftheceo.htm |
| EX-31.1 - EXHIBIT 31.1 CERTIFICATION OF THE CEO SECTION 302 - CELGENE CORP /DE/ | ex311certificationoftheceo.htm |
| EX-10.5 - EXHIBIT 10.5 CELGENE CORPORATION 2008 STOCK INCENTIVE PLAN - CELGENE CORP /DE/ | celgeneincentivestockplana.htm |
| 10-Q - 10-Q - CELGENE CORP /DE/ | a2015063010q.htm |
| EX-31.2 - EXHIBIT 31.2 CERTFICATION OF THE CFO SECTION 302 - CELGENE CORP /DE/ | ex312certificationofthecfo.htm |
Exhibit 10.27
Summary of 2015 Compensation Package
Name | Scott A. Smith | |||||
Job Title | President, Inflammation & Immunology | |||||
Base Salary | $650,000 | Effective March 1, 2015 | ||||
Bonus Target | 75% | Effective January 1, 2015 | ||||
Annual Equity Award | Stock Options | Performance Stock Units | Restricted Stock Units | Effective February 17, 2015 | ||
Threshold | Target | Maximum | ||||
34,500 | 3,100 | 6,200 | 12,400 | 3,500 | ||
Severance Benefit | Lump sum 12 months of base salary Lump sum 12 months of bonus at target 12 months COBRA benefit at active employee rates, less applicable taxes | In the event of involuntary termination for reasons other than cause | ||||
"Double Trigger" due to Change in Control | All severance benefits Unvested RSUs and Options would fully vest Change in control payments would be reduced to avoid 280G excise tax, if beneficial to employee | In the event of position elimination due to change in control | ||||
Financial Planning Benefit | Up to $15,000 per year | Reimbursement of reasonable and customary fees associated with financial planning and/or tax preparation/advice | ||||
Acknowledged and agreed: | On behalf of Celgene Corporation: | |||||
/s/Scott A. Smith | July 27, 2015 | /s/Robert J. Hugin | July 27, 2015 | |||
Scott A. Smith | Date | Robert J. Hugin | Date | |||